Berita
Prilenia Berencana Mengajukan Permohonan Izin Edar di Uni Eropa untuk Pridopidin pada Penyakit Huntington
Prilenia announced today that they plan to submit a Marketing Authorization Application in the EU for the use of Pridopidine in the treatment of Huntington’s Disease. According to Dr. Michael Hayden, CEO of Prilenia “Pridopidine demonstrates consistent treatment benefits across Baca lebih lanjut...